quantitative
Analysis v1
Strong Support
Semaglutide might be better than other similar weight-loss drugs at protecting heart health in people who are overweight or obese but don’t have diabetes.
65
0
Evidence from Studies
Supporting (1)
65
Community contributions welcome
65
Comparison of glucagon-like peptide-1 receptor agonists vs. placebo on any cardiovascular events in overweight or obese non-diabetic patients: a systematic review and meta-analysis
Systematic Review With Meta-Analysis
Human
2024The study looked at weight-loss drugs called GLP-1 agonists in people who are overweight but don’t have diabetes, and found that semaglutide works better than the others at lowering heart risks.
Contradicting (0)
0
Community contributions welcome
No contradicting evidence found
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.